LIPOFOR Film-coated tablet Ref.[28221] Active ingredients: Gemfibrozil

Source: Υπουργείο Υγείας (CY)  Revision Year: 2018  Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus

4.1. Therapeutic indications

Lipofor is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
  • Primary hypercholesterolaemia when a statin is contraindicated or tolerated.

Primary prevention

Reduction of cardiovascular morbidity in males with increased non-HDL cholesterol and at high risk or first cardiovascular event when a statin is contraindicated or not tolerated (see section 5.1).

4.2. Posology and method of administration

Prior to initiating gemfibrozil, other medical problems such as hypothyroidism and diabetes mellitus must be controlled as best as possible and patients should be placed on a standard lipid-lowering diet, which should be continued during treatment. Lipofor should be taken orally.

Posology

Adult

The dose range is 900 mg and 1200 mg daily.

The only dose with documented effect on morbidity is 1200 mg daily.

The 1200 mg dose is taken as 600 mg twice daily, half an hour before breakfast and half an hour before the evening meal.

The 900 mg dose is taken as a single dose half an hour before the evening meal.

Elderly (over 65 years old)

As for adults

Children and adolescents

Gemfibrozil therapy has not been investigated in children. Due to the lack of data the use of Lipofor in children is not recommended.

Patients with renal impairment

In patients with mild to moderate renal impairment (Glomerular filtration rate 50 – 80 and 30 - <50 ml/min/1.73 m², respectively), start treatment at 900 mg daily and assess renal function before increasing dose. Lipofor should not be used in patients with severely impaired renal function (see section 4.3).

Patients with hepatic impairment

Gemfibrozil is contraindicated in hepatic impairment (see section 4.3).

Method of administration

Oral administration.

4.9. Overdose

Overdose has been reported. Symptoms reported with overdosages were abdominal cramps, abdominal LFT’s, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. The patients fully recovered. Symptomatic supportive measures should be taken if overdose occurs.

6.3. Shelf life

5 years.

6.4. Special precautions for storage

Store below 25°C. Protect from light and moisture.

6.5. Nature and contents of container

PVC/Aluminium blisters. Pack-sizes of 30 and 100 film-coated tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.